Pharmaceutical Directory

Pharmaceutical Directory – A Complete A to Z Directory for Indian Pharmaceutical & Biopharmaceutical Industry. PharmaExpress directory is FREE to add and curated by PharmaExpress – Directory Services Team.

Lupin Ltd

Lupin Ltd

Corporate Overview


Headquartered in Mumbai, India, Lupin Limited today is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.

Dr. Desh Bandhu Gupta’s vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic pharmaceutical companies globally.

Lupin first gained recognition when it became one of the world’s largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments. The Company’s R&D endeavours have resulted in significant progress in its NCE program. The Company’s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin’s world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realize its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has emerged as the 5th largest and the fastest growing Top 5 company in the U.S (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS) and the fastest growing top 10 Generic players in Japan and South Africa. (IMS), Today, Lupin also has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 5th by prescriptions & growing at 52 %) and Japan (ranked 7th and growing at 23%). Lupin’s Consolidated Revenues and Profit after Tax were Rs. 57,068 million and Rs. 8,626 million for FY 2010-11.

Going forward, our research backbone, best-in-class class manufacturing capabilities, marketing and servicing depth globally will stand us in good stead. The company will continue to focus on identifying and developing niche segments, a differentiated product portfolio in all its chosen markets backed up by strategic partnerships and in-licensing, and investment in new areas such as biosimilars – well on-course to becoming a global pharmaceutical powerhouse.


The Lupin Story


The company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for. The Lupin flower is known to nourish the land, the very soil it grows in. The Lupin flower is also known to be tolerant of infertile soils and capable of pioneering change in barren and poor climes. The Lupin flower and bean pods have also long been used as food and sources of nourishment, thus protecting and nurturing life.

Embedded inLupin was a formula for growth. Forty-four years on, what has stayed with us is that same entrepreneurial spirit, culture of creativity and innovation and pride in belonging to an industry that makes a difference in the lives of people.

We are today a fully integrated pharmaceutical company with an unrivaled position in the US, India and Japan. This position is built on a backbone of cutting-edge research, world-class manufacturing facilities and a truly global supply chain. With the building blocks in place, the future looks brighter than its ever been. We are Built to Grow.


Built to Grow

Lupin is poised and ready for its future. We have all the elements in place to play a major role in the global pharmaceutical landscape and to continue our mission of delivering consistent high growth in revenues, margins and returns for our Company and its stakeholders.

Our culture of growth is built upon trust and transparency in all our dealings and in all our relationships. Be those relationships with our customers, our investor communities, our people or society at large. We are proud to be part of an industry that can make a real difference to people’s lives. We now stand ready to grasp opportunities emerging in a new world. Global economies are going though challenging times. Over our 44-year history we have been through such cycles before and we have learnt that a firm foundation, a passionate growth ethic embedded in a sound business strategy, underpinned by a strong balance sheet are the essentials for success.

A thirst for growth has been the common thread binding us with our heritage. But for us, growth is not just the numbers; it is our part in enhancing the knowledge, experience and talent of our people that we value and nurture. We are an agile organization, working as a global team, creating and unlocking value. Lupin is Built as One, Built to Enrich.


Our Vision

“An Innovation Led,
Transnational Pharmaceutical Company”

“Our aspiration is to become a multi-billion dollar transnational company and be counted amongst the top generic pharmaceutical companies in the world. Going forward, we have to consistently set ourselves standards and benchmarks that will be world-class but uniquely Lupin.”

Dr Desh Bandhu Gupta

“Today, Lupin is at a very interesting point of its evolution, well on course on its intended journey to emerge as a global generics powerhouse – a point in time where I find not only a new level of energy and excitement brewing within Lupin’s rank and file, but most importantly, a keen sense of pointed urgency to achieve and excel.”

Dr Kamal Sharma
Managing Director

Chairman’s Message

“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”

My Dear Shareowners

When I started Lupin over 40 years ago, the dream was simple – to provide as many people as possible with affordable medicines that would address the most prevalent diseases of the highest social priority, such as tuberculosis. I discovered that by working hard on a noble ambition, growth and success followed.

Embedded in Lupin is a formula for this growth. Growth fuelled by a boundless vision, the determination to succeed and reach for our dreams. These fundamental philosophies are what drive Lupin – creativity, performance and innovation.

Lupin has delivered the highest growth performance consistently over the past ten years. We expect the future to be no different and we continue to invest in new therapy areas, reach out to new territories and dive deeper into our existing markets. As we have grown as a company, we realized that our ambitions were bigger than generic products alone and that we had the means to go up the value chain into specialty products and proprietary research and development. That is the journey we are on today – to become a global specialty pharmaceutical company offering a wide portfolio of generic and proprietary products.

As always, it is a pleasure for me to address you and to share our results for the previous year. We have carefully put together all the pieces of our story, to be counted amongst the leading pharmaceutical companies in the world. Lupin is Built to Grow.

With Best Wishes,
Dr. Desh Bandhu Gupta
Founder and Chairman
Lupin Limited


2012 Lupin bags “Niryat Shree” Gold Trophy for ‘outstanding export performance’ in the category of chemicals, drugs, pharma and allied products, during the year 2009-2010, by FIEO (Federation of Indian Export Organisations).
Lupin has been recognised as “India’s Best Company to Work For” in the Biotech and Pharmaceutical sector, in the survey conducted by the Great Place to Work Institute ® and the Economic Times.
Dr Desh Bandhu Gupta (Founder & Chairman) has won the ‘Ernst & Young Entrepreneur of the Year 2011′ Award in the Life sciences and Healthcare sector.
Lupin has won the NDTV Business Leadership Awards, 2011: Indian Pharmaceutical Company of the Year
Mrs Vinita Gupta won the Business Today ’30 Most Powerful Women in Business’ award.
Mr Ramesh Swaminathan won the Business Today Yes Bank ‘Best CFO Award – Best Leverage Management – Large Companies’
2011 Healthcare Distribution Management Association (HDMA) Honors Lupin with DIANA Award for Best Overall Generic Product Manufacturer
Top Indian Pharma company under the ‘Pharmaceuticals’ sector for the Dun & Bradstreet – Rolta Corporate Awards 2010.
Lupin ranked amongst India’s Top 3 ‘Best Companies to Work For’ in Healthcare and Pharma Sector.
Hall of Fame Award by Chemtech Foundation (Leadership and Excellence Awards)
IMM (Institute of Marketing and Management) Award for Excellence as Top Organisation.
Lupin ranked 2nd amongst India’s “Best Companies to Work for” in the Biotechnology and Pharmaceutical Sector.
2010 Indian Pharmaceutical Company of the Year 2010″ by Frost & Sullivan India Excellence in Healthcare Awards 2010.
Best Drug Development Company, Asia’ by The New Economy Pharmaceutical & Healthcare Awards 2010
Lupin wins ‘The Most Promising Entrant into the Big League’ by CNBC India Business Leader Awards 2010
2009 International Excellence Award by Institute of Economic Studies.
Outstanding Export Performance Award by Pharmexcil (Pharmaceuticals Export Promotion Council of India)



History & Milestones


Year Milestones
2011 Lupin Acquires I’rom Pharmaceuticals through its Japanese Subsidiary.
Lupin and Medicis Enter into Joint Development Agreement.
Lupin acquires Worldwide Rights for the Goanna® Brand.
2009 Lupin acquired majority stake in Multicare Pharmaceuticals Philippines Inc.
2008 Lupin expanded its product basket in Japan-Kyowa and received ten products approval from Ministry of Health & Labour Welfare, Japan.Lupin acquired Hormosan Pharma GmbH, a Generic Company in Germany.Lupin acquired stake in Generic Health Pty Ltd., in Australia.Lupin acquired Pharma Dynamics in South Africa.
2007 Lupin acquired Vadodara based Rubamin Laboratories Ltd (rechristened to Novodigm Ltd).Lupin acquired Kyowa Pharmaceutical Industry Company Limited, a leading Generic Company in Japan.Commercial production was started at the New finished dosage facility at Jammu.Lupin received “Best new manufacturer of the year” award from Amerisource Bergen.
2006 A new facility was set up at Jammu.Maiden Bonus share were issued in the ratio of 1:1.Maiden issue of Foreign Currency Convertible Bonds (FCCB) aggregating US $100 mn, which are listed on Singapore Stock Exchange.
2005 Maiden Employees Stock Option Plan was implemented.US FDA and MHRA (UK) approvals were received for Goa.New Lovastatin plant at Tarapur was approved by the US FDA.
2004 WHO approval was received for State of the art formulation Plants at Goa and Aurangabad.
2003 Lupin had successfully implemented SAP ERP across the Company to unify all business functions and processes.Introduced collaborative messaging and workflow solution on the intranet.Oral Cefaclor injectible Plant at Mandideep was approved by US FDA.Lupin Pharmaceuticals Inc. USA, was formed for trading, marketing and developmental activities in the US.
2002 Exports to the Advanced Markets crossed Rs.1000 mn.Rising trend of exports as a % of total revenue – up 33% year-over-year.Patent filings crossed 100.Five ANDAs were filed.

New Anti-TB facility was commissioned at Aurangabad.

Rablet was rated by ORG-Marg as the second best launch of FY 2002-03.

2001 Lupin became the only Asian Pharmaceutical company to receive US FDA approvals for its sterile cephalosporin facility.A state of the art US FDA approvable oral cephalosporin bulk active plant was commissioned.State of the art R&D Centre at Pune was commissioned.Lupin commenced supply of Cephalosporin bulk actives to its alliance partners in the US.

Lupin Laboratories Ltd was amalgamated with Lupin Chemicals Ltd, whose name was changed to Lupin Limited.

2000 The Cefotaxime facility was approved by the US FDA.The Company’s restructuring operations yielded encouraging results.Work commenced on the R&D Centre at Pune.
1999 Lupin’s injectable cephalosporin bulk active plant at Mandideep was approved by UK MCA.
1997 Lupin’s injectable Cephalosporins dosages plant at Mandideep obtained UK MCA approval.Lupin’s formulations facility at Aurangabad was upgraded.Three plants of Lupin, manufacturing Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur, got US FDA approvals.ICMA Technology award was given for injectable Cephalosporins.
1996 Government of India conferred the ‘Best Exporter’ Award on Lupin.Company received the ICMA Technology award for injectable Cephalosporins.
1992 Fermentation Plant of Lupin Chemicals Ltd was established at Tarapur, Maharashtra.Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.Lupin Laboratories Ltd and Lupin Chemicals Ltd raised money through IPOs in 1993-94.Won FICCI’s award for contribution towards rural development.
1991 Injectable cephalosporin (bulk and dosages) production was initiated at Mandideep.Lupin won the ICMA technology award for successfully manufacturing Vitamin B6.
1989 Joint venture in Thailand – Lupin Chemicals (Thailand) Ltd was established.Two Plants Ankleshwar and Mandideep received US FDA approvals for maintaining stringent quality standards.
1988 The Lupin Human Welfare and Research Foundation (LHWRF) was founded by Dr Desh Bandhu Gupta to provide an alternative, sustainable and replicable model of rural development.
1987 Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar went on stream.
1981 Ethambutol production was started
1980 Lupin commissioned a formulations plant and an R&D center at Aurangabad.
1972 Lupin Laboratories Pvt Ltd was incorporated.
1968 Lupin commenced business.
B/4 Laxmi Towers,
Bandra Kurla Complex, Bandra (E),
+91 22 6640 2130
+91 22 6640 2222

Send Message to listing owner

Lupin Ltd